OBJECTIVE: The aim was to determine the response rate and @entity137 of topotecan administered Days 1-3 every 21 days for recurrent @entity5 of the ovary, peritoneum, or fallopian tube. A 3-day regimen may be more convenient and less expensive than a 5-day schedule. METHODS: @entity1 with recurrent @entity43 , peritoneum, or fallopian tube who had adequate hepatic, renal, and hematologic function were eligible for participation. Topotecan (2 mg/m(2)) was administered for 3 consecutive days every 21 days. Response was measured clinically and serologically. Granulocyte colony stimulating factors (GCSF) were not utilized prophylactically, but could be added under specific conditions. RESULTS: Thirty-one @entity1 with recurrent @entity43 whose median age was 63 (range 32-84) received 165 cycles of topotecan (median = 6; range 2-8) and are evaluable for @entity137 . The median number of prior regimens was 1. Topotecan was administered on schedule in 96.6% of cycles. Grade 3/4 @entity1398 was seen in 29.1 and 23.6% of courses, respectively; but only 3.4% of cycles required GCSF support (6 cycles for 2 @entity1 ). Grade 4 @entity882 was rare (1% of cycles). Nonhematologic @entity137 was mild. The response rate for 28 evaluable @entity1 was 32.1% (10.7% complete response (CR) and 21.4% partial response (PR)); stable disease was seen in 17.9% of @entity1 . The median progression-free interval (PFI) for all @entity1 was 15.5 weeks (range 5-40). Eighteen @entity902 -sensitive @entity1 demonstrated a 43.4% response rate (12.5% CR and 31.3% PR); stable disease was documented in 18.8%. The median PFI for @entity902 -sensitive @entity1 was 18.5 weeks (range 5-40). CONCLUSION: Topotecan is an effective regimen with acceptable @entity137 for recurrent @entity43 when administered for 3 consecutive days (2 mg/m(2)) every 21 days. It can be delivered on schedule without GCSF support in the vast majority of @entity1 .

Three-consecutive-day topotecan is an active regimen for recurrent XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer', 'epithelial cancer of the ovary'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['epithelial cancers'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity43 :: (MESH:D010051,Disease) :: ['epithelial ovarian cancer']
